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Characteristics and outcomes of patients with lymphoma undergoing PCI are unknown. 
Therefore, we analyzed clinical characteristics and outcomes in patients that underwent 
percutaneous coronary intervention (PCI) and had a concomitant diagnosis of Hodgkin’s 
(HL) or non-Hodgkin’s (NHL) lymphoma. We analyzed patients with and without lymphoma 
diagnosis from the Nationwide Inpatient Sample in the US who underwent PCI procedure 
during 2004-2014. Multivariable regression analysis was performed to examine the 
association between lymphoma diagnosis and clinical outcomes post-PCI including short-
term complications and in-hospital mortality. A total of 7,119,539 PCI procedures were 
included in the analysis and 18,052 patients had a diagnosis of lymphoma (0.25%). These 
patients were likely to experience in-hospital mortality (OR 1.39, 95%CI 1.25-1.54), stroke 
or transient ischemic attack (TIA) (OR 1.75, 95%CI 1.61-1.90), and any in-hospital 
complication (OR 1.31, 95%CI 1.25-1.37), following PCI. In the lymphoma subtype-
analysis, diagnosis of HL was associated with an increased odds of in-hospital death (OR 
1.40, 95% CI 1.24-1.56), any in-hospital complication (OR 1.31, 95% CI 1.25-1.38), bleeding 
complications (OR 1.12 95% CI 1.05-1.20) and vascular complications (OR 1.13 95%CI 
1.06-1.20) while these odds were not significantly associated with NHL diagnosis. Finally, 
both types of lymphoma were associated with an increased odds of stroke/TIA following PCI 
(OR 1.82, 95% CI 1.67-1.99 and OR 1.31, 95% CI 1.05-1.63, respectively). In conclusion, 
while the prevalence of lymphoma in the observed PCI cohort was low, a diagnosis of 
lymphoma was associated with an adverse prognosis following PCI, primarily in patients 
with the HL diagnosis.  
















Cardiovascular disease and cancer constitute two leading causes of death worldwide and it is 
expected that their prevalence and coexistence will further increase due to the aging 
population and shared risk factors.
1-3
 Percutaneous coronary intervention (PCI) is the 
commonest form of revascularization in patients with coronary artery disease (CAD), with 
increasingly complex and multi-morbid patients undergoing these procedures.
2
 On the other 
hand, lymphomas are one of the most common hematological malignancies accounting for 
about 3% to 4% of all cancers worldwide
 
with cancer registries ranking it as the second 
commonest hematological malignancy.
4-6
 Patients with lymphoma have an increased risk of 
fatal cardiovascular events compared to the general population
7
 and can develop severe 
CAD
8
 often enhanced by radiotherapy and chemotherapeutic treatment.
9
 Whilst patients with 
lymphoma are at increased risk of developing CAD which is more complex and extensive, 
there have been no previous studies reporting on the outcomes following PCI in patients with 
concomitant hematologic malignancies such as lymphoma. The aim of the present study was 
to report on clinical and procedural characteristics and outcomes of patients with a confirmed 
diagnosis of Hodgkin's (HL) or non-Hodgkin's lymphoma (NHL) and to compare them to 
patients without lymphoma, in a nationwide contemporary cohort. 
Methods 
The data was obtained from the Nationwide Inpatient Sample (NIS) for hospital 
discharges in the United States (US) during the period of 2004-2014. The NIS is the largest 
publicly available all-payer inpatient health care database in the US that was developed for 
the Healthcare Cost and Utilization Project (HCUP) through Federal-State-Industry 
partnership sponsored by the Agency for Healthcare Research and Quality (AHRQ). The NIS 


















All patients aged 18 or older that had a confirmed discharge record of performed PCI 
during the index hospitalization between January 2004 and December 2014 were initially 
included in the analysis. To identify all eligible discharge records that underwent PCI from 
the NIS dataset we used respective International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) procedure codes. Discharge codes that were captured are 
presented in Supplementary Table 1A. 
Patient sociodemographic variables were recorded for each hospital discharge and 
included information about age, gender, race and ethnicity, length of stay (LOS), admission 
type (elective or emergent), admission day (weekday or weekend), median ZIP household 
income, expected primary payer, total hospitalization charge in US$, and Charlson 
Comorbidity Index (CCI). Since the total bill charged by the hospital does not correspond to 
the actual payer-end cost, these charges were multiplied by the conversion ratio in order to 
approximate actual final cost for the payer. Each discharge record also contained diagnosis 
codes for patient's diagnoses established during the index hospitalization such as ST-
elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) 
and cardiogenic shock. Finally, patient comorbidities and medical history items in terms of 
cardiovascular and cerebrovascular events were retrieved from the aforementioned diagnosis 
codes assigned to each discharge and were recorded as well. 
Procedural PCI variables were identified by using respective procedure codes and 
included information on the type of vessel revascularization (single vessel or multi-vessel 
PCI) and whether PCI of the bifurcation lesion was performed. Additionally, data on the use 














procedures (such as the use of intracoronary pressure wire or intravascular ultrasound) and 
type of stent implanted (DES, drug-eluting stent or BMS, bare-metal stent) were recorded. 
Patients with current lymphoma diagnoses on record were identified by using 
respective ICD-9 codes (Supplementary Table 1B). Main clinical outcomes of interest in 
this study were in-hospital mortality and complications associated with the PCI procedure. 
These complications included bleeding, vascular complications, cardiac complications, and 
post-procedural stroke or transient ischemic attack (TIA). Events of interest were captured by 
using patient safety indicators and ICD-9-CM codes (Supplementary Table 1C). 
All data analyses were performed using IBM SPSS Statistics for Windows, version 
25.0 (IBM, Armonk, NY, USA) and STATA 14.0 (StataCorp, College Station, Texas, USA). 
Continuous variables were presented as median and interquartile range (IQR) or mean ± 
standard deviation (SD) where appropriate. Categorical variables were presented as number 
and/or percentage.  Discharge cases that had greater than 10% missing data for included 
outcomes and covariates were removed from the analysis while random missing of data was 
assumed. For data analysis, sampling weights were applied, as provided by the NIS design. 
Due to the complexity and longitudinal nature of NIS database and changes in sampling and 
weighting strategies over time, recommendations from AHRQ to apply weights at discharge 
were followed since this procedure reduces the margin of error for estimates and delivers 
more stable estimates. 
Multivariable logistic regression analysis was undertaken to examine the association 
between the cases with a diagnosis of lymphoma, irrespective if Hodgkin's or non-Hodgkin's, 
compared to cases without lymphoma on designated clinical endpoints including in-hospital 
mortality, specified complications and the composite outcome of aggregated complications. 
In the secondary regression analysis, separate associations of two main subtypes of 














compared to patients without lymphoma. To account for potential confounders, all regression 
models were adjusted for age, gender, median income, expected payer, elective admission, 
weekend admission, primary diagnosis of MI, STEMI/NSTEMI, diagnosis of cardiogenic 
shock, use of an assisting device or IABP, stent type, multi-vessel PCI, bifurcation stenting, 
fractional-flow reserve use, intravascular ultrasound use, hospitalization year,  CCI, smoking, 
diabetes mellitus, hypercholesterolemia, arterial hypertension, atrial fibrillation, and previous 
CAD, MI, PCI, coronary artery bypass grafting (CABG) or stroke/transient ischemic attack 
(TIA). Finally, a propensity score-matched (PSM) analysis was performed in order to match 
respective cohorts (lymphoma vs. no lymphoma patients and HL vs. NHL patients) in terms 
of age, sex and baseline factors and for this nearest-neighbor matching algorithm was used 
with caliper size of 0.2. Rates of short-term complications and in-hospital mortality were then 
compared between respective groups that were adjusted for PSM coefficient. 
Results 
A total of 7,119,539 hospital discharges from 2004 to 2014 were identified with PCI 
performed during the index hospitalization. Discharge cases that had greater than 10% 
missing data for included outcomes and covariates such as age, gender, elective procedure 
indication, length of stay, and median income according to ZIP code, were excluded from the 
analysis, as shown in Figure 1. In total, about 0.61% (N=43,917) of the original dataset was 
removed due to missing data while 76.4% of these removed records were due to missing 
median ZIP code income data. Excluded patients did not significantly differ from those 
included in any of the measured outcomes and in most of baseline characteristics 
(Supplementary Table 1D). Crude comparison of women and men with lymphoma 
diagnosis undergoing PCI in respect to short-term complications and in-hospital mortality is 
provided in Supplementary Table 1E. The average prevalence of patients with a diagnosis 














Furthermore, there seems to be an increasing trend (significant at p<0.001) of PCI utilization 
in lymphoma patients during the studied NIS period (Figure 2). 
Baseline sociodemographic, clinical and procedural characteristics of patients with 
lymphoma and patients without lymphoma that underwent PCI are presented in Table 1. 
Patients with lymphoma tended to be older, of White Caucasian race, and were less likely to 
be admitted for an elective PCI procedure compared to non-lymphoma patients. A proportion 
of cases in which Medicare was designated as a primary expected payer was significantly 
higher in lymphoma patients than those without lymphoma. Furthermore, lymphoma patients 
were significantly more comorbid, tended to stay longer in hospital, and were charged more 
per hospitalization compared to non-lymphoma patients. Lymphoma patients also more 
commonly presented with NSTEMI during index hospitalization and had a higher incidence 
of cardiogenic shock compared to those without lymphoma. A previous history of CAD, 
AMI, CABG, and PCI was generally less prevalent among patients with lymphoma than 
those without, and this was also the case for traditional cardiovascular risk factors such as 
hypercholesterolemia, smoking, arterial hypertension, and uncomplicated diabetes mellitus. 
Regarding PCI procedural characteristics, lymphoma patients were more likely to 
undergo multivessel revascularization with BMS implantation, accompanied with more 
frequent intracoronary pressure wire and/or intravascular ultrasound procedures. Similarly, 
LV assist devices or IABP were more likely to be used during PCI procedure in lymphoma 
patients which corresponds to a higher prevalence of cardiogenic shock among lymphoma 
patients. Regarding the lymphoma type, NHL patients were more likely to be older, have 
higher comorbidity burden, a longer median LOS, and higher cost of hospitalization 
compared to patients with HL. Furthermore, patients with NHL were more likely to present 
with NSTEMI, be admitted over a weekend, and undergo multivessel coronary 














intracoronary pressure wire during PCI compared to HL patients. In contrast, HL patients 
were more likely to present with STEMI, undergo DES implantation, and suffer a cardiogenic 
shock at presentation, accompanied with more frequent use of LV assist device or IABP 
(Table 1). 
Patients with a current diagnosis of lymphoma had significantly higher rates of 
complications and in-hospital mortality after PCI, compared to patients without lymphoma. 
This difference was most prominent for bleeding and vascular complications which were 
more than twice more common among patients with lymphoma than those without. 
Furthermore, NHL patients had significantly higher rates of bleeding, vascular complications, 
composite of complications, and post-procedural stroke/TIA, compared to HL patients 
undergoing PCI. The rate of cardiac complications following PCI and in-hospital mortality 
were similar between both types of lymphoma (Table 2). Depiction of complication and in-
hospital mortality rates among patients with HL, NHL and patients without lymphoma is 
provided in Figure 3. 
Furthermore, in the multivariable regression model adjusted for multiple covariates, a 
diagnosis of lymphoma was independently associated with a significantly increased odds of 
bleeding (OR 1.12, 95% CI 1.06-1.19), vascular complications (OR 1.11, 95% CI 1.05-1.18) 
and composite of complications (OR 1.31, 95%CI 1.25-1.37) following PCI, compared to 
patients without lymphoma set as a reference, while this effect was not significant in the case 
of cardiac complications (Table 3). Finally, a diagnosis of lymphoma was associated with a 
significant 39% increase in odds of in-hospital death (OR 1.39 95% CI 1.25-1.54) and a 75% 
increase in odds of post-procedural stroke or TIA (OR 1.75, 95%CI 1.61-1.90) following 
PCI, compared to non-lymphoma patients.  
Furthermore, when stratified by lymphoma type, diagnosis of HL was independently 














procedural stroke/TIA, 12% increase in odds of bleeding, 13% increase in odds of vascular 
complications, and, finally, 31% increase in the likelihood of any complication, when 
compared to no-lymphoma diagnosis. In contrast, no significant association was observed 
between NHL diagnosis and any short-term complication except for post-procedural 
stroke/TIA (Table 3). Multivariate-adjusted odds ratios for each of measured outcomes in 
respect to lymphoma type are summarized in Figure 4. 
When adjusted for propensity score, comparator analysis confirmed that HL patients 
had significantly higher rates of bleeding and vascular complications than NHL patients, as 
well as post-procedural stroke/TIA and any complications while both groups did not differ in 
terms of in-hospital mortality and cardiac complications (Table 4). Similarly, PSM analysis 
confirmed that lymphoma patients had significantly more short-term adverse events and 
higher in-hospital mortality compared to patients without lymphoma (Table 5). 
Discussion 
Our analysis of over 7 million PCI procedures, suggests that lymphoma diagnosis is 
independently associated with an increased odds of adverse short-term clinical outcomes, 
higher rates of bleeding, vascular complications and in-hospital mortality. This was mainly 
limited to patients with HL once adjustments for differences in baseline characteristics were 
applied. No comparable studies, to our knowledge, have reported on clinical outcomes among 
lymphoma patients undergoing PCI.  
A recent study published by our group reported that approximately to one in ten 
patients who underwent PCI in the United States until 2014 had a current or a prior history of 
cancer, but there is paucity of published data specifically in patients with lymphoma.
2
 
Hematologic malignancies drive thromboembolic disease through multiple procoagulant, 
fibrinolytic and proteolytic factors and by activating inflammatory pathways, while these 














immunomodulatory agents that are routinely used to treat these conditions.
11,12
 The 
thrombotic risk in lymphomas is substantially higher in adult patients with NHL compared to 
those with HL, especially in advanced stages of disease for which more aggressive 
therapeutic strategies are employed while this risk is also partially driven by the typically 
older age of NHL patients.
13,14
 
In our analyzed cohort, patients with NHL were significantly older compared to both 
HL patients and those without lymphoma with a greater comorbidity burden, higher 
proportion of PCI procedures for ACS indications, more multivessel PCI, a worse 
cardiovascular risk factor profile, and more likely to have diabetes and renal failure. 
Moreover, patients with NHL had a substantially higher prevalence of atrial fibrillation that 
may suggest more widespread use of anticoagulation agents. All these factors might have 
predisposed patients to more bleeding events, but also to more thrombotic complications and 
finally, short-term death following PCI. Once the higher risk profile of patients with NHL 
was adjusted for differences in baseline covariates, NHL was no longer associated with an 
increased odds of in-hospital mortality or short-term complications. 
In contrast, our associations with adverse outcomes and a concomitant diagnosis of 
HL, persisted even when differences in baseline risk factor profile were adjusted for. Patients 
with hematological malignancies such as those with HL are predisposed to increased risks of 
thrombosis, however, 95% of these complications occur during treatment, hence it is difficult 
to ascertain whether the prothrombotic effect is induced by the ongoing treatment or the 
lymphoma itself.
13
 The average incidence of thrombosis among lymphoma patients is 6%, 
with more advanced stages of the disease incrementally increasing the risk of thrombosis, 
both in HL and in NHL, while there also seems to be an effect of certain chemotherapeutics 
affecting this risk.
13-15
 Patients with hematologic malignancies such as those with HL are also 














thrombocytopenia, clotting factor deficiencies, defects in vascular integrity
16
, and use of 
anticoagulant agents.
17,18
 Both HL and NHL diagnosis were associated with an increased 
odds of stroke/TIA following PCI although this odds ratio was more prominent among HL 
patients. In the HL population, irradiation to the neck and mediastinum was the most 
important risk factor for ischemic stroke and TIA.
19
 Given that intensive radiotherapy 
regimens were historically used in HL patients it could be that cerebrovascular events have 
been partially driven by generally higher irradiation burden among HL patients, compared to 
those with NHL. 
Presented results suggest that interventional cardiologists should liaise with 
oncologists and hematologists and adopt a multi-disciplinary approach in managing these 





 Patients deemed to be at increased risk of major bleeding could be treated with 
DES platforms that only require abbreviated dual antiplatelet therapy, and judicious use of 
intravascular imaging to reduce the risk of stent thrombosis.
22
 Radial access should be the 
default access site used where possible, to minimize access site-related major bleeding 
complications.
23-25
 Antiplatelet regimes should be individualized to balance the risk of 
ischemic and major bleeding complications in close discussion with both hematologists and 
cardio-oncologists as advocated by relevant cardiovascular societies. 
26,27,28
 
There are several limitations to our study. This is a large registry-based study with all 
inherent limits of such study design and an impossibility to ascertain causal effects between 
variables. Underreporting and coding errors might be a source of bias in our analysis. 
Furthermore, data on disease duration, complete blood count, coagulation parameters, current 
or past treatments, stage/grade of lymphoma, history of radiation therapy and radiation dose, 
as well as the use of chemotherapeutics, antiplatelet, and anticoagulation agents were not 














Even more, a diagnosis of NHL in this study was comprised of heterogeneous NHL cancer 
subtypes that vary greatly with respect to their biology and prognosis, therefore, might have a 
different impact on endpoints of interest. 
In conclusion, this study shows that patients with lymphoma are more likely to sustain 
complications and in-hospital death following PCI. These increased odds appear to be mainly 
observed in HL patients, although the odds of cerebrovascular events are significantly 
increased in both lymphoma types. There is a paucity of studies in this patient population and 
findings from this study provide important data which can better inform patients, caregivers 
and their treating physicians. These findings should encourage cardiologists to pursue care in 
close collaboration with the oncologists in order to improve outcomes. 
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Figure 1. A study flow diagram showing inclusion and exclusion criteria and the final 


















Figure 2. Trends in prevalence of lymphoma patients that underwent PCI among all patients 



















Figure 3. Percentage (%) of procedural complications and in-hospital mortality events among 


















Figure 4. Multivariable-adjusted odds ratios and 95% confidence intervals for procedural 
outcomes and in-hospital mortality among patients that underwent PCI with Hodgkin's and 














































Age at index admission, 
years [IQR] 
65 [56,74] 55 [48-65] 71 [62-79] <0.001 <0.001 
Charlson Comorbidity 
Index (mean ± SD) 
1.07 ± 1.25 2.98 ± 1.29 3.22 ± 1.42 <0.001 <0.001 
Median length of stay, 
days [IQR] 
2 [1-4] 2 [1-4] 3 [2-5] <0.001 <0.001 











Men 66.3% 68.4% 66.9% 0.105 0.014 
Ethnicity    <0.001 <0.001 
White 79.0% 83.8% 86.9%   
Black 8.0% 6.4% 4.8%   
Hispanic 6.8% 3.9% 4.2%   
Asian/Pacific Islander 2.2% 1.6% 1.5%   
Native American 0.5% 0.0% 0.2%   
Other 3.6% 4.3% 2.4%   
Household Income    <0.001 <0.001 
1
st
 quartile 26.6% 20.7% 21.9%   
2
nd
 quartile 26.8% 22.4% 24.6%   
3
rd
 quartile 24.6% 24.7% 26.0%   
4
th
 quartile 22.0% 32.3% 27.4%   
Paying modality    <0.001 <0.001 
Medicare-primary payer 51.3% 34.6% 68.0%   
Medicaid-primary payer 5.7% 6.2% 3.9%   
Private insurance-
primary payer 
34.8% 53.5% 24.6%   
Self-pay 4.9% 2.8% 1.4%   
No charge 0.5% 0.4% 0.2%   
Other 2.8% 2.6% 1.8%   















Admission day, Weekday 16.0% 16.5% 18.0% 0.045 <0.001 
Single coronary vessel 
revascularization 
73.3% 71.9% 71.3% 0.496 <0.001 
Multivessel coronary 
revascularization 
17.8% 19.3% 19.9% 0.336 <0.001 
Bifurcation stenting 1.7% 1.3% 1.6% 0.133 0.092 
Use of left ventricular 
assist device or intra-
aortic balloon pump 
3.3% 6.6% 4.8% <0.001 <0.001 
Cardiogenic shock at 
presentation 
2.8% 4.8% 3.7% 0.001 <0.001 
ST-Elevation myocardial 
infarction 
21.3% 22.8% 19.4% <0.001 <0.001 
Non-ST-elevation 
myocardial infarction 
22.9% 26.3% 29.3% <0.001 <0.001 
Fractional Flow Reserve 
pressure wire used during 
percutaneous coronary 
intervention 
0.7% 0.7% 1.3% 0.004 <0.001 
Intravascular ultrasound 
used during percutaneous 
coronary intervention 
4.8% 7.6% 6.2% 0.005 <0.001 
Bare-metal stent 
implanted 
28.3% 30.9% 38.6% <0.001 <0.001 
Drug-eluting stent 
implanted 
73.2% 70.3% 62.9% <0.001 <0.001 
History of coronary 
artery disease 
94.6% 93.4% 92.3% 0.025 <0.001 
History of percutaneous 
coronary intervention 
18.7% 20.3% 16.9% <0.001 <0.001 
History of coronary 
artery bypass grafting 
7.3% 7.4% 6.8% 0.238 0.017 
History of myocardial 
infarction 
13.2% 13.9% 12.1% 0.005 0.006 
History of 
cerebrovascular incident 
3.8% 3.5% 4.2% 0.053 0.005 
Acquired immune 
deficiency syndrome 
0.1% 1.0% 0.6% 0.012 <0.001 
Alcohol abuse 2.0% 1.9% 1.1% 0.002 <0.001 
Smoker 35.2% 31.4% 27.0% <0.001 <0.001 
















Congestive heart failure 1.0% 1.7% 2.2% 0.088 <0.001 
Chronic obstructive 
pulmonary disease 
15.5% 15.0% 17.6% <0.001 <0.001 
Diabetes mellitus, 
uncomplicated 
33.2% 23.4% 29.6% <0.001 <0.001 
Arterial hypertension 69.6% 54.7% 64.2% <0.001 <0.001 
Atrial fibrillation 10.0% 7.7% 16.1% <0.001 <0.001 
Hypercholesterolemia
+
 65.9% 59.2% 58.4% 0.358 <0.001 
Obesity
++
 12.2% 9.6% 8.4% 0.020 <0.001 
Renal failure 9.6% 7.4% 13.9% <0.001 <0.001 
Liver disease 0.9% 1.5% 0.9% 0.006 0.004 
Peripheral vascular 
disorders 
10.4% 7.2% 10.5% <0.001 <0.001 
Paralysis 0.7% 1.0% 0.7% 0.076 0.209 
Dementia 1.4% 0.6% 1.2% 0.001 0.001 
History of leukaemia 0.3% 1.2% 1.4% 0.238 <0.001 
History of solid tumour 
without metastasis 
1.2% 1.5% 2.7% <0.001 <0.001 
*Comparison of Hodgkin’s vs Non-Hodgkin’s lymphoma group; ** Comparison of No lymphoma vs. 
Lymphoma group 
+
Increased plasma concentration of cholesterol carried in low-density lipoproteins (LDL) and/or increased total 
cholesterol in plasma 
++






















Table 2. Complications and in-hospital mortality stratified by lymphoma diagnosis  















3.0% 5.0% 7.7% <0.001 <0.001 
Vascular 
complications 
3.3% 5.8% 7.8% 0.001 <0.001 
Cardiac 
complications 
2.4% 2.6% 3.0% 0.098 <0.001 
Post-procedural 
stroke/TIA 
3.0% 2.8% 3.6% 0.031 <0.001 
Any 
complication 
8.1% 10.1% 13.5% <0.001 <0.001 
In-hospital 
mortality 
1.6% 2.1% 2.7% 0.096 <0.001 


















Table 3. Odds ratios* and 95% confidence intervals and level of significance (p-value) for 











































































*Multivariable regression model was adjusted for age, sex, median income, expected payer, elective admission, 
weekend admission, primary diagnosis of MI, STEMI/NSTEMI diagnosis, diagnosis of shock, use of an assist 
device or IABP, the type of stent used, multi-vessel PCI, bifurcation stenting, fractional flow reserve, 
intravascular ultrasound, year of hospitalisation, Charlson Comorbidity Index, smoking status, 
hypercholesterolemia, arterial hypertension, atrial fibrillation, diabetes mellitus, history of coronary artery 

















Table 4. Propensity score-matched* comparison of Hodgkin’s and Non-Hodgkin’s 
Lymphoma patients in respect to short-term complications and in-hospital mortality 





Bleeding complication 6.0% 4.7% 0.028 
Vascular complications 6.8% 4.9% 0.002 
Cardiac complications 2.2% 2.7% 0.054 
Post-procedural stroke/TIA 3.3% 1.6% <0.001 
Any complication 11.6% 9.6% 0.035 
In-hospital mortality 1.6% 1.8% 0.656 
*Propensity score-matched analysis used exact matching on age while additional covariates in the model were 
sex, Charlson Comorbidity Index, day of admission, non-elective procedure, median household income, obesity, 
smoking, arterial hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, chronic pulmonary 
disease, congestive heart failure, renal failure, multivessel disease, bifurcation lesion, cardiogenic shock, ST-
elevation myocardial infarction, drug-eluting stent use, and previous history of coronary artery disease, 
percutaneous coronary intervention, myocardial infarction, cerebrovascular incident and coronary artery bypass 
grafting. Caliper length was set at 0.2. 
 
 
Table 5. Propensity score-matched* comparison of patients without and with lymphoma in 
respect to short-term complications and in-hospital mortality 





Bleeding complication 7.2% 8.4% <0.001 
Vascular complications 5.1% 7.2% <0.001 
Cardiac complications 2.8% 3.8% <0.001 
Post-procedural stroke/TIA 2.1% 3.5% <0.001 
Any complication 9.8% 12.8% <0.001 
In-hospital mortality 2.6% 3.6% <0.001 
*Propensity score-matched analysis used exact matching on age while additional covariates in the model were 
sex, Charlson Comorbidity Index, day of admission, non-elective procedure, median household income, obesity, 
smoking, arterial hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, chronic pulmonary 
disease, congestive heart failure, renal failure, multivessel disease, bifurcation lesion, cardiogenic shock, ST-
elevation myocardial infarction, drug-eluting stent use, and previous history of coronary artery disease, 
percutaneous coronary intervention, myocardial infarction, cerebrovascular incident and coronary artery bypass 
grafting. Caliper length was set at 0.2. 
 
